Gemfibrozil, a lipid-lowering drug, can cause myopathy, a muscle disorder. This risk is higher in patients with chronic renal failure, highlighting the need for careful monitoring.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background: